drugset / Trial / NCT01281527

Paliperidone Palmitate Flexible Dosing in Schizophrenia

NCT01281527

Phase 3 Completed 1044 enrolled Janssen-Cilag International NV
NaSingle-groupOpen-labelTreatment

Summary

This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.

Timeline

Start
2010-11
Primary completion
2012-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 75 mg Intramuscular

Indications